Liquidia Technologies to Highlight Print® Technology at the World Vaccines CongressRESEARCH TRIANGLE PARK, NC – April 08, 2015
Liquidia Technologies today announced that it will highlight the diverse capabilities of the company’s PRINT® (Particle Replication In Non-Wetting Templates) technology in vaccine development at the 15th World Vaccines Congress being held at the Walter E. Washington Convention Center in Washington, DC from April 7 – 9, 2015.
Dr. Michele Stone, Executive Director of Vaccines at Liquidia, will be presenting Utilizing PRINT Technology to Advance Vaccine Development on April 9 at 12:00pm EDT in Ballroom B.
The PRINT technology is an innovative, highly tunable and scalable particle engineering process that allows Liquidia to precisely tailor particle size, shape, charge, hydrophobicity, and composition with the goal of optimizing a vaccine’s ability to elicit the desired immune response. By using a broad range of matrix materials formulated with antigens and adjuvants, Liquidia has leveraged its PRINT technology to design unique particle systems to generate superior humoral and cellular immune responses.
Liquidia is harnessing the unique capabilities of its PRINT technology to find innovative solutions that can address many of the challenges often encountered in vaccine development with the ultimate goal of creating safe and efficacious vaccines that can provide the broadest possible protection for a global population.